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ABSTRACT
HANNAH LYNN CARSON: The Histone Deacetylase Inhibitor Largazole: A
Potential Chemotherapeutic Agent
(Under the advisement of Drs. Yu-Dong Zhou and Dale Nagle)

Histone deacetylase enzymes are known for their inherent activity as
epigenetic modifiers. Although, they have become recognized for their role in cancer
progression and other diseases. But also, histone deacetylases have other non-histone
targets, for example, microtubules, which play important roles in cancer metastasis,
apoptosis, and replication. With histone deacetylase inhibitors (HDACi), our research
explored HDACi effects on breast cancer cell lines. The overall goal was to
understand the potential of largazole, a class one histone deacetylase inhibitor on
breast cancer cell lines. The research consisted of two parts: sulforhodamine B (SRB)
viability assays under hypoxic and normoxic conditions. The specific cell lines that
were used were MCF-7, MCF-7 BoM, MDA-MB-231, and MDA-MB-231 BoM. The
results of the experiments showed that histone deacetylase inhibitors, specifically
Largazole is a useful chemotherapeutic agent against breast cancer. Also, Hypoxic
conditions in combination with cycloheximide did lead to lower cell proliferation.
The MCF-7 and MDA-231 had greater inhibition in normoxic condition. The BoM
cell lines had greater inhibition in both conditions. And as expected the triplenegative did require a greater largazole concentration for effect to take place in the
hypoxic conditions. The extremely aggressive cancer cell-line MDA-MB-231 gave
the most conclusive results.
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INTRODUCTION: BREAST CANCER

Through the years I have known many women who have triumphed through
the diagnosis of breast cancer. This disease is the most common cancer and primary
cause of cancer related death in females (Akram 1). Meaning that about 12% of
women in the U.S. will develop breast cancer in their lifetime (breastcancer.org).
This year alone, roughly 42,000 women are expected to die from breast cancer
(breastcancer.org). These startling facts are what push researchers and medical
professionals to work for a cure to ensure a healthier future for women.
When a student is learning about cancer the first piece of information that is
taught is that there are eight remarkable Hallmarks of cancer, they are: “sustaining
proliferative signaling, evading growth suppressors, resisting cell death, enabling
replicative immortality, inducing angiogenesis, reprogramming energy metabolism,
evading immune response, and activating invasion and metastasis.”(Hanahan 1).
Recognition of these cancer hallmarks are what lead researchers to understand more
about cancer and potential ways to cure this disease. Although, research is fascinating
and continues to make great discoveries every day. Women can take part in
preventative medicine to reduce the risks of breast cancer. John Hopkins lists the
following as preventative healthcare: “take care of yourself emotionally, physically,
reduce stress, eat healthy, and see the doctor for regular health screenings” (John
Hopkins, 1). Although these were listed for women to reduce the risk of breast cancer,
this advice is useful for all cancer prevention.
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The bad news is there is only so much that women can do, there are also nonmodifiable factors, those cannot be prevented; such as age, race, mutated genes,
family and personal history, late menopause, and even height are all associated with
a predisposition to breast cancer. According to the Center of Disease Control and
Prevention, 1 out of 10 women are diagnosed with some form of breast cancer under
the age of 45 due to the BRCA1 and BRCA2 mutation, descent of the Ashkenazi
Jewish heritage, exposure to radiation, or a close relative diagnosed with breast
cancer or ovarian cancer before the age of 45 (CDC 1). Another non-modifiable
factor is breast density, related to rather a woman's breast being more fibrous or
glanderous than fat, leading to greater density in the breast causing it to be more
difficult to locate tumors using a mammogram.
In general, breast cancer is generally described at ductal or lobular, other
forms exist as well but are less common such as tubular, mucinous, medullary, and
papillary. Lobular carcinomas begin in the milk producing glands, whereas; ductal is
in cells of the milk duct (MD Anderson 1). Each tumor is different and unique, and
the prognosis is dependent on the type of tumor. For example, those diagnosed with
mucinous (colloid) carcinoma tend to have a better prognosis than those diagnosed
with an invasive ductal carcinoma (Susan G. Komen 1). There are also three types of
molecular receptor-based classifications of breast cancers, these include HER2, ER,
and triple-negative (MD Anderson 1). The HER2 (Human Epidermal Growth Factor
receptor 2) is positive, then the cancer will be reluctant to respond to hormone
therapies, because the receptor works specifically to cause growth of cancer cells.
The ER-positive breast cancer (Estrogen Receptor) is another possible source of
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promoting cancer cell growth. Triple-negative breast cancer is known to spread much
faster because it lacks ER, PR (Progesterone Receptors), and does not overexpress
HER2 growth receptors, anti-hormone therapies are not useful (cancer.org 1). As
seen through all the breast cancer variations and the risk of women, the goal of
researchers and doctors is to find the best course of action for each individual patient.
Cancer results from a combination of mutations. The genes in our body are carried
in the DNA molecules, and if a mutation occurs it can change the amount or activities
carried out by particular proteins (Weinburg 1). Specifically, these cancer related
genes are called proto-oncogenes and modifications of tumor suppressor genes,
which lead to uncontrolled cell proliferation. Many proto-oncogenes relay growth
signals from the outside of the cell to the deep interior, when the mutation occurs the
growth signaling pathway remains continuously active when it should be silent
(Weinberg 2). These growth factors promote cancer metastasis. For example,
approximately one-third of women who are sentinel lymph node negative at the time
of surgical resection of the primary breast tumor will subsequently develop clinically
detectable secondary tumors (Hunter 1). Simply put with metastatic breast cancer
there is risk that removal of the tumor could lead to an increase in the circulation of
cancer cells in the body leading to cancer at a distal sight. Metastatic breast cancer is
stage IV, although not always caused by surgery the cancer may just progress to the
point of spreading to local or distal sights. With experiments and countless hours in
the lab Drs. Zhou and Nagle allowed me and my lab partner Hannah McCowan to
study possible ways to stop metastatic breast cancer. The use of histone deacetylase
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inhibitors, specifically the marine natural product largazole, could be a potential
answer to prevent malignant breast cancer.

Histone Deacetylase Inhibitors
The human genome contains approximately 3.2×109 nucleotides—is
distributed over 24 different chromosomes (Johnson 1). The chromosome contains
long, linear DNA associated with proteins and contains those that are used in gene
expression and DNA replication and repair (Johnson 1). Histone modifications are
what allow gene expression, for example histone acetylation allows for higher
expression (Harb 2). “Histone acetylation status is regulated by two groups of enzymes
exerting opposite effects, histone acetyltransferases (HATs) and histone deacetylases
(HDACs).” (Harb 3).
The definition of an inhibitor is an agent that slows or interferes with a
chemical action (Merriam webster). These inhibitors can interfere with epigenetic
enzymes created through mutations caused by cancer in the body. These epigenetic
enzymes cause modifications in the methylation and histone modifications and cause
extensive changes without altering the DNA sequence (Han 1). Specifically, “Histone
acetylation is an important epigenetic modification that mainly occurs in the Nterminal region of the histone tail.” (Han 5). The acetylation acts to weaken the
binding between DNA and histones, ultimately leading to relaxed chromatin causing
increased gene expression (Han 5).The acetylation occurs and cause neutralization of
the positive charges by binding with lysine residues, this process can decrease the
affinity for DNA. Because of this, researchers know that “histone acetylation alters
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nucleosomal conformation” leading to increased availability of transcription
regulatory proteins (Struhl 1). This could cause overexpression and lead to cancer.
“Mutations in genes encoding HDACs are associated with the progression of tumors,
owing to the abnormal transcription of key genes that regulate important cellular
functions such as cell proliferation, cell cycle regulation and apoptosis,” (Han 5) and
certain histone deacetylase (HDAC) inhibitors can be used as anticancer agents.
These are important agents because the histone acetylases are used in determination
of gene expression (West 1). Whereas, the deacetylase is useful in the regulation
process as it removes the acetyl group from the histone (West 1). The inhibition of
HDAC1 and HDAC2 can cause hypersensitivity in cancer cells. But in the past,
histone deacetylase inhibitors have only been useful on nontumor forming cancers.
Specifically, blood cancers like leukemia and T-cell subcutaneous lymphoma.
Largazole
The natural product largazole is a cyclic depsipeptide, from marine Symploca
sp. cyanobacteria with novel chemical scaffold that potently inhibits class I histone
deacetylases. (Hong 1). The mechanism of action of largazole is similar to drugs like
vorinostat (Zolinza®) and romidepsin (Istodax®), Vorinostat is a drug that inhibits class
I, II, and IV HDAC molecules and romidepsin inhibits class I HDAC molecules
(Hong1). The Symploca sp. extract was originally collected in Key Largo, Florida;
where it was found to have remarkable antiproliferative activity (Hong 2).The name
largazole was due to the occurrence in Key Largo and the “azole” because of the one
thiozole linearly fused to a 4-methylthiazoline (Hong 2). Largazole contains only one
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non modified standard amino acid and three stereogenic centers. Its 3-hydroxy-7mercapto-hept-4-enoic acid is unique among marine natural products.

13

Figure 1. Largazole Structure

The cytotoxicity of the drug was tested on different tumor cell lines (i.e., colorectal
carcinoma, breast cancer, neuroblastoma, and osteosarcoma) and was shown to inhibit their
growth at nanomolar concentrations. Remarkably, non-transformed epithelial cells and
fibroblasts were less sensitive to its effects (Hong2-3). Mechanism of action studies indicated
that the antiproliferative activity of largazole results from the inhibition of HDAC enzymes
(Hong 3). Because of the functionality of the thioester suggested that through hydrolysis
largazole could be converted into a HDAC inhibitor (Hong 3). “Largazole activation appears
to be induced through a general protein-assisted mechanism, which may explain why
largazole itself displayed apparent activity in the in vitro enzymatic assay with recombinant
HDAC1 enzyme, although with about 10-fold lower potency.” (Hong 3). The thiol in
largazole presents itself to be stable in freeform and reversible adduct, could result in
hijacking of proteins for delivery to the target site. But denatured proteins did not form
adducts with largazole thiol. In addition, it has been found that largazole lacks acute toxicity,
resulting in largazole being a potentially safe anticancer HDAC inhibitor (Hong 8).
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Figure 2: Mechanism of action. A) Modes of action of largazole and FK228 to
liberate potent HDAC inhibitors. B) Molecular docking of largazole thiol into an HDAC1
homology model. PG = Protecting group.

Histone Deacetylase Inhibitor Experiment

The research for this project began in the Fall of 2018 under the guidance of Drs.
Zhou and Nagle. The first part of the project began with a cancer research course to learn the
background of cancer and specifics of breast cancer. The next semester the time was spent
in the lab learning important laboratory procedures and techniques to sufficiently carry out
the experiments. Beginning in Fall of 2019 the official research project began, the team
developed a project and the actual experiments were put into place. The overall goal was to
discover the effects of largazole in varying concentrations, on breast cancer cells. Therefore,
the HDACi(s), specifically HDAC I inhibitors were studied. The general hypothesis of this
experiment was to understand the effects of HDACi(s) on breast cancer cells.

MATERIALS AND METHODS
Background Research
15

With the decision to pursue the use of HDAC(i)’s as a form of cancer treatment, the real
research began. This process began with mini lectures each time learning more and more of what
each experiment would entail. Afterwards we began to gather what was needed to conduct the
experiments. Dr. Zhou specifically mentioned studying largazole and its effects on breast cancer.
The overall research design was to discover the effects of differing concentrations of largazole
on four different cancer cell lines. Largazole was obtained from Professor Luesch at the
University of Florida College of Pharmacy. The human cancer cell lines were the MCF-7 (ductal
carcinoma), MDA-MB-231 (breast adenocarcinoma), and subtypes MDA-MB-231 BoM and
MCF-7 BoM, these were all from ATCC. The MDA-MB-231 was from a 51-year-old Caucasian
woman with triple negative breast cancer from a pleural effusion. Sadly, this is an aggressive
tumor with a poor prognosis. The MCF-7 was from a 69-year-old Caucasian woman with triplenegative breast cancer, the unique aspect about this tumor is its ER-positive, meaning it grows
with response to the hormone estrogen. The MCF-7 BoM cell line was from a bone secondary
metastasis acquired from Dr. J Massagué’s lab at the Sloan Kettering Cancer Center. And our
research group specifically received the cells from Dr. Konosuke Watabe at Wake Forest
University.

Sulforhodamine B (SRB) Viability Assay
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The SRB Viability Assay was developed to measure the drug-induced cytotoxicity
(voigt 1). The method is useful in discovering the cell density determination depending on
the amount of cellular protein content (Viachi 1). This is a useful method because it can test
large samples in a matter of days and the materials used are inexpensive. Therefore, SRB is
a useful and cost-effective method of screening. For this experiment to take place it is broken
up into four main steps: preparation of treatment, incubation of the cells with a treatment, fix
the cells and add the SRB staining, and measure the absorbance (Orellana 1). Beginning the
experiment, the cell cultures were trypsinized with 1 mL (Trypsin). The cells were then
washed with 10 mL of 10% fetal calf serum (FCS) media. Then the 100 μL of solution and
10% FCS were seeded to each well on a 96-well plate, at varying concentrations ranging
from 30,000 cells/mL, 20,000 cells/mL, and 15,000 cells/mL. The cells were then cultured
at 37℃ with 95% air and 5% CO2 creating a humid environment. The 96-well plates were
then infused with the chemotherapeutic drug, largazole which was prepared by serial
dilutions. The cells were then incubated for 48 hours and afterwards a 100 μL of media was
removed for the cell wells. A cell count was then performed to ensure that cells were seeded.
And the process of cell fixation began by adding 100 μL of 20% trichloroacetic acid (TCA)
and 1% phosphate-buffered saline (PBS) solution into each of the wells. The PBS that was
available was 10% so it was diluted with autoclaved water. The plates were then refrigerated
at 4℃ for an hour. After the removal of the plates from the refrigerator the plates were then
washed down with tap water from the sink four separate times. After the wells in the plates
were dry, the wells were then stained with 100 μL of 4% SRB containing 1% Acetic acid
and the plates sat at room temperature with the stain for a total of 10 minutes. Afterwards
each well was washed three times with 1% acetic acid and then left to dry. A 100 μL of 10%
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Tris buffer was added to the stained wells and were lightly shaken for 10 minutes on the
microplate genie. The plates were then read by the SpectraFlour plus machine and Magellen
software at the absorbance range of 490 nm to 620 nm. Overall, the sulforhodamine B dye
is what binds to the proteins of the cell specifically the basic amino acids, which allows for
the calculation of the inhibition value using the Magellen software. This inhibition value can
be calculated by using the total protein mass per wall (indicated by the SRB dye) which is
causally related to the cell density of that specific cell.

Hypoxic and Normoxic Experiments

Hypoxic conditions are defined as cells, tissues, or organs that lack sufficient oxygen.
Hypoxia can be caused by the presence of tumors in the body and the cells can learn to adapt
to that environment. During hypoxia, hypoxia-inducible factor-1 (HIF-1) is activated to
regulate various genes such as those involved in angiogenesis or oxygen transport. The
stabilization of this transcription factor is a hallmark of hypoxia, therefore detecting elevated
levels of HIF-1 is used to screen for tumors hypoxia. (Wu 1). Part of the experiment after the
SRB Assay was performed, the research team decided to see the effects of hypoxia on the
cells after treatment with largazole. This was accomplished by putting one set of plates in
the Hypoxia chamber with a petri dish containing sterilized water, this allows for adequate
humidification of the cells. The other set of cells were placed in normoxic conditions as a
control. In the hypoxia chamber the conditions were set at 1% O2 gas mixture. In order to
remove most of the oxygen from the chamber it was flushed by opening the gas tank. And
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the gas flow was turned off and the chamber was closed completely. Following the de-gasing
process the chamber was then returned to normal incubation.
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Results and Discussion
SRB Viability Assay

The results of the sulforhodamine B viability assay show the percent inhibition of
values of largazole tested on MCF-7, MCF-7 BoM, MDA-MB-231, and MDA-MB-231 BoM
cell lines. One goal of the viability test was to determine the IC50 values (the half-maximal
inhibitory concentration when measuring the potency of a substance in inhibition). Although
the results provided inhibition, the IC50 value was not attained because more than 50% was
inhibited. The figures below show the results of viability due to varying largazole
concentrations depending on hypoxic and normoxic conditions. Also, bar graphs in comparing
media control versus cycloheximide. My lab partner and I configured the data together and
processed the graphs through graph pad.
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Figure 3. The effect of largazole on MCF-7 cell proliferation/viability under
hypoxic conditions. Data shown are average +/- standard deviation of the mean from one
experiment performed in triplicate.

Figure 4. The effect of largazole on MCF-7 cell proliferation/viability under
normoxic conditions. Data shown are average +/- standard deviation of the mean from one
experiment performed in triplicate
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Figure 5. The effect of largazole on MCF7-BoM cell proliferation/viability under
hypoxic conditions. Data shown are average +/- standard deviation of the mean from one
experiment performed in triplicate

Figure 6. The effect of largazole on MCF7-BoM cell proliferation/viability under
normoxic conditions. Data shown are average +/- standard deviation of the mean from one
experiment performed in triplicate
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Figure 7. The effect of largazole on MDA-MB-231 cell proliferation/viability under
hypoxic conditions. Data shown are average +/- standard deviation of the mean from one
experiment performed in triplicate

Figure 3. The effect of largazole on MDA-MB-231 cell proliferation/viability under
normoxic conditions. Data shown are average +/- standard deviation of the mean from one
experiment performed in triplicate
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Figure 9. The effect of largazole on BoM cell proliferation/viability under normoxic
conditions. Data shown are average +/- standard deviation of the mean from one
experiment performed in triplicate

Figure 10. The effect of largazole on BoM cell proliferation/viability under
normoxic conditions. Data shown are average +/- standard deviation of the mean from one
experiment performed in triplicate
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Figure 11. MCF-7 cell line effects on cell growth/viability under hypoxic/normoxic
and the effects of cycloheximide.

Figure 12. MCF7- BoM cell line effects on cell growth/viability under
hypoxic/normoxic and the effects of cycloheximide
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Figure 13. MDA-MB-231 cell line effects on cell growth/viability under
hypoxic/normoxic and the effects of cycloheximide

Figure 14. MDA-MB-231 BoM cell line effects on cell growth/viability under
hypoxic/normoxic and the effects of cycloheximide.

The first eight graphs in the figures above represent tumor cell viability in relation to
hypoxic and normoxic controls and the effects of cycloheximide in comparison to media
controls. In each graph it is evident that the hypoxic control leads to a smaller percent
inhibition in comparison to normoxic conditions. Therefore, it can be said that hypoxia
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conditions cause the cell lines to be less susceptible to cytotoxic effects of the drug largazole.
As expected, the triple negative required a higher concentration of largazole in hypoxic
conditions. Triple negative breast cancer is one of the most difficult to treat, therefore
requiring a higher drug concentration. The hypoxic and normoxic conditions had the least
effects on the MCF-7 and MDA-MB-231 BoM cell lines. It can be stated that the normoxic
control does produce a higher percent inhibition overall. The MCF-7 BoM cell line provided
drastic results between the hypoxic and normoxic conditions, further proving that normoxic
conditions produce a much larger percent inhibition. The negative values are evidence of
error for example improper serial dilutions. For more reliable data all four cell lines should
be further tested to attain IC50 values.
An interesting data trend was provided by the last four figures. The media control
was overall less effective than cycloheximide, a highly toxic fungicide. In each of the finding
less cell proliferation was found in each cell line due to the use of 10 μM cycloheximide.
Also, in the data shown above, the majority of the time the hypoxia condition leads to equal
or lower cell proliferation in regard to media control and cycloheximide; with exception to
the MCF-7 BoM, the media control hypoxic condition was higher than under normoxic
conditions. Overall, the growth inhibition never reached complete inhibition and was most
prominent at the highest concentrations of largazole.
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Conclusion
An overview of the analysis of the SRB viability assay and the hypoxia versus
normoxia conditions of multiple different cell lines, our hypothesis largazole does have an
impact on cell lines, as does hypoxic and normoxic conditions. The MCF-7 and MDA-231
had greater inhibition in normoxic condition. The BoM cell lines had greater inhibition in
both conditions. And as expected the triple-negative did require a greater largazole
concentration for effect to take place in the hypoxic conditions. The four cell lines, MCF-7,
MCF 7 BoM, MDA-MB-231, and MDA-MB-231 BoM had variation in inhibitor effects in
SRB viability assays. This is most likely due to human error, possibly not accurate dilutions.
Therefore, further testing should be done. Also, more research should be conducted at higher
concentrations to attain IC50 values of the marine natural product largazole. The use of
cycloheximide did prove to be effective and the hypoxic conditions did lead to lower cell
proliferation. In order, to improve the results more testing should be done at a higher
cycloheximide concentration direct comparison of largazole and cycloheximide.
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